Who are Testosterone Undecanoate and/or PDE-5's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/testosterone-undecanoate-and-or-pde-5.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Testosterone Undecanoate and/or PDE-5 — Competitive Intelligence Brief

Testosterone Undecanoate and/or PDE-5 (Testosterone Undecanoate and/or PDE-5) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Androgen replacement therapy combined with PDE-5 inhibitor. Area: Endocrinology / Urology.

marketed Androgen replacement therapy combined with PDE-5 inhibitor Androgen receptor (testosterone undecanoate); phosphodiesterase-5 (PDE-5 inhibitor component) Endocrinology / Urology Small molecule Live · refreshed every 30 min

Target snapshot

Testosterone Undecanoate and/or PDE-5 (Testosterone Undecanoate and/or PDE-5) — Hospital Santa Fe. Testosterone undecanoate replaces deficient testosterone while PDE-5 inhibitors enhance erectile function by increasing nitric oxide signaling in penile vasculature.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Testosterone Undecanoate and/or PDE-5 TARGET	Testosterone Undecanoate and/or PDE-5	Hospital Santa Fe	marketed	Androgen replacement therapy combined with PDE-5 inhibitor	Androgen receptor (testosterone undecanoate); phosphodiesterase-5 (PDE-5 inhibitor component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Androgen replacement therapy combined with PDE-5 inhibitor class)

Hospital Santa Fe · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Testosterone Undecanoate and/or PDE-5 — Competitive Intelligence Brief. https://druglandscape.com/ci/testosterone-undecanoate-and-or-pde-5. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab